11/12/2024
1:34 PM | Corbus Pharmaceuticals (Subject)
VANGUARD GROUP INC (Filed by)
| Form SC 13G/A | |
11/12/2024
8:37 AM | Adage Capital Management, L.P. (Filed by)
Corbus Pharmaceuticals (Subject)
| Form SC 13G/A | |
11/07/2024
3:58 PM | Corbus Pharmaceuticals (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
11/07/2024
7:41 AM | Corbus Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/04/2024
10:28 AM | Corbus Pharmaceuticals (Subject)
VANGUARD GROUP INC (Filed by)
| Form SC 13G/A | |
11/04/2024
6:51 AM | Corbus Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/22/2024
5:06 PM | BlackRock, Inc. (Filed by)
Corbus Pharmaceuticals (Subject)
| Form SC 13G | |
|
10/15/2024
3:19 PM | Corbus Pharmaceuticals (Subject)
MILLENNIUM MANAGEMENT LLC (Filed by)
| Form SC 13G/A | |
09/24/2024
3:04 PM | Chen Bihua (Reporting)
Corbus Pharmaceuticals (Issuer)
Cormorant Asset Management, LP (Reporting)
Cormorant Global Healthcare Master Fund, LP (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/04/2024
3:44 PM | CATLIN AVERY W (Reporting)
Corbus Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/03/2024
3:52 PM | Corbus Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/20/2024
3:45 PM | Corbus Pharmaceuticals (Issuer)
Kung Winston (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
08/20/2024
3:48 PM | Corbus Pharmaceuticals (Issuer)
Kung Winston (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/20/2024
7:15 AM | Corbus Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/06/2024
3:42 PM | Corbus Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/18/2024
4:58 PM | Cohen Yuval (Reporting)
Corbus Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/18/2024
4:59 PM | Corbus Pharmaceuticals (Issuer)
Moran Sean F. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/17/2024
8:21 AM | Corbus Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/14/2024
4:25 PM | Cohen Yuval (Reporting)
Corbus Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/14/2024
4:25 PM | Corbus Pharmaceuticals (Subject)
Moran Sean F. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/03/2024
3:30 PM | Corbus Pharmaceuticals (Issuer)
Salzmann Peter (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/03/2024
3:31 PM | CATLIN AVERY W (Reporting)
Corbus Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/03/2024
3:32 PM | Corbus Pharmaceuticals (Issuer)
Jenkins John Kenneth (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/03/2024
6:08 AM | Corbus Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/31/2024
3:39 PM | Corbus Pharmaceuticals (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
05/20/2024
3:30 PM | Corbus Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/09/2024
7:00 AM | Corbus Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/07/2024
7:30 AM | Corbus Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/11/2024
8:17 AM | Corbus Pharmaceuticals (Issuer)
Moran Sean F. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/10/2024
3:58 PM | Corbus Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/10/2024
3:59 PM | Corbus Pharmaceuticals (Filer)
| Form DEFA14A | |
03/22/2024
4:05 PM | Corbus Pharmaceuticals (Filer)
| Form PRE 14A | |
03/20/2024
11:15 PM | Corbus Pharmaceuticals (Filer)
| Form EFFECT | |
03/20/2024
4:07 PM | Corbus Pharmaceuticals (Filer)
| Form 424B3 | |
03/20/2024
4:10 PM | Corbus Pharmaceuticals (Filer)
| Form 10-K/A | |
03/20/2024
4:13 PM | Corbus Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/13/2024
3:52 PM | Corbus Pharmaceuticals (Filer)
| Form S-3
Registration statement under Securities Act of 1933 | |
03/12/2024
4:19 PM | Corbus Pharmaceuticals (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/12/2024
7:15 AM | Corbus Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/11/2024
4:34 PM | Chen Bihua (Reporting)
Corbus Pharmaceuticals (Issuer)
Cormorant Asset Management, LP (Reporting)
Cormorant Global Healthcare Master Fund, LP (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/29/2024
4:13 PM | Corbus Pharmaceuticals (Issuer)
Smethurst Dominic (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
Trump’s Back, but DC’s Coming for Your Money! (Ad) Trump's back in the White House, ready to hit the gas on America's comeback.
He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs.
But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back… Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov |
02/29/2024
4:07 PM | Corbus Pharmaceuticals (Issuer)
Smethurst Dominic (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
02/14/2024
3:45 PM | Corbus Pharmaceuticals (Subject)
K2 HealthVentures Equity Trust LLC (Filed by)
| Form SC 13G/A | |
02/14/2024
2:19 PM | Cohen Yuval (Reporting)
Corbus Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/14/2024
2:26 PM | Corbus Pharmaceuticals (Issuer)
Moran Sean F. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/05/2024
3:47 PM | Corbus Pharmaceuticals (Subject)
Cormorant Global Healthcare Master Fund, LP (Filed by)
| Form SC 13G | |
02/05/2024
7:12 AM | Corbus Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/01/2024
7:55 PM | Corbus Pharmaceuticals (Filer)
| Form 8-K/A | |
02/01/2024
4:27 PM | Corbus Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/01/2024
4:09 PM | Corbus Pharmaceuticals (Filer)
| Form 424B5 | |
01/31/2024
8:16 AM | Corbus Pharmaceuticals (Filer)
| Form S-3MEF | |
01/30/2024
7:40 PM | Corbus Pharmaceuticals (Filer)
| Form 424B5 | |
01/30/2024
7:41 PM | Corbus Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/30/2024
5:07 PM | Corbus Pharmaceuticals (Issuer)
HOLMER ALAN F (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/30/2024
3:56 PM | Cohen Yuval (Reporting)
Corbus Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/30/2024
3:18 PM | Chen Bihua (Reporting)
Corbus Pharmaceuticals (Issuer)
Cormorant Asset Management, LP (Reporting)
Cormorant Global Healthcare Master Fund, LP (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
01/30/2024
3:23 PM | Chen Bihua (Reporting)
Corbus Pharmaceuticals (Issuer)
Cormorant Asset Management, LP (Reporting)
Cormorant Global Healthcare Master Fund, LP (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/29/2024
3:40 PM | Corbus Pharmaceuticals (Subject)
Point72 Asset Management, L.P. (Filed by)
| Form SC 13G | |
01/29/2024
6:30 AM | Corbus Pharmaceuticals (Filer)
| Form 424B3 | |
01/29/2024
6:31 AM | Corbus Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/09/2024
7:45 AM | Corbus Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
